Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Armodafinil (Nuvigil) vs Omega-3: Omega-3 has the stronger overall evidence (9 vs 5/10); they're alternatives for sharpen focus — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Omega-3 wins 3 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
Top outcomes
Verdict
Probably helps
10 of 15 studies with measurable effects showed benefit.
Top outcomes
Approved dosing is 150–250 mg once daily in the morning for narcolepsy and OSA, or 150 mg taken ~1 hour before the start of a night shift for shift-work disorder. A prescription drug; off-label cognitive use is not an approved or standardized regimen.
Morning
Oral tablet (armodafinil)
2-3g combined EPA+DHA daily (a typical label dose, not the dose used in the cited trials, which gave 1 g or 3.25 g of omega-3 a day, or 1 to 4 g of fish oil a day without stating its EPA+DHA content)
With meals containing fat
Triglyceride form fish oil
Hours (per dose); weeks for steady benefit
Per dose (acute)
Acute / weeks
Throughout use
4-8 weeks
2-4 weeks
Immediate
4-12 weeks
The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy.
Current medical research and opinion (2006) · Rct · n=196
Pivotal 12-week, multicenter, double-blind, placebo-controlled RCT in 196 narcolepsy patients (armodafinil 150 mg, 250 mg, or placebo once daily)
Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults.
Clinical therapeutics (2006) · Rct
12-week, 37-center, double-blind, placebo-controlled RCT of armodafinil 150 or 250 mg as adjunct in nCPAP-adherent OSA/hypopnea patients with residual excessive sleepiness
Armodafinil for treatment of excessive sleepiness associated with shift work disorder: a randomized controlled study.
Mayo Clinic proceedings (2009) · Rct · n=254
12-week, 42-site, randomized, double-blind, placebo-controlled RCT in 254 night-shift workers with moderate-or-greater shift work disorder (armodafinil 150 mg vs placebo before each shift)
Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
The New England journal of medicine (2019) · Rct · n=25871
During a median follow-up of 5.3 years, a major cardiovascular event occurred in 386 participants in the n-3 group and in 419 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.80 to 1.06; P=0.24).
Omega-3 fatty acids for intermittent claudication
The Cochrane database of systematic reviews (2024) · Meta analysis · n=1830
Omega-3 compared with a control may have little to no effect on ankle-brachial index (MD -0.02, 95% CI -0.08 to 0.04; 3 studies, 168 participants; very low-certainty evidence).
A systematic review and meta-analysis of the omega-3 fatty acids effects on brain-derived neurotrophic factor (BDNF)
Nutritional neuroscience (2024) · Meta analysis · n=587
12 RCTs with 587 subjects: omega-3 supplementation increased serum BDNF versus placebo (SMD 0.72, 95% CI 0.28 to 1.15), with high heterogeneity (I2 = 84.39%).
The points are the dose bands of a meta-analysis of 10 randomised trials with 1,426 adults (PMID 37028202): EPA-rich products at 1 to under 2 g of EPA a day reduced depression severity (SMD -0.43), while 2 g a day or more did not (SMD -0.20, not significant), so the 2 g point is plotted as no effect. Doses are grams of EPA, not EPA plus DHA. The Cochrane review of 33 placebo-controlled trials found a small to modest effect, unlikely to be clinically meaningful and rated very low certainty, with no difference in remission or response (PMID 34817851). No trial compared doses directly.
AI-estimated from published studies. Interpret as directional guidance.
Omega-3 has a higher evidence score (9/10 vs 5/10) and wins in 3 of 3 categories.
For sharpen focus, Armodafinil (Nuvigil) has a higher relevance score (48 vs 20).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The honest tier list — proven staples vs situational vs mostly marketing. The hub the other guides feed into.
On Ozempic/Wegovy/Mounjaro? What actually helps — muscle preservation, GI relief, nutrient gaps (no upsell).
Which supplements clash with blood thinners, thyroid meds, antibiotics & more — and what to do.
Caffeine+L-theanine works; bacopa needs weeks; most "brain pills" are hype. The honest tier list.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.